Limits...
Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops.

Amza A, Goldschmidt P, Einterz E, Huguet P, Olmiere C, Bensaid P, Bella-Assumpta L - PLoS Negl Trop Dis (2010)

Bottom Line: One year after the second treatment, the prevalence decreased to 3.1% (95%CI 2.0-4.9), a total reduction of 90%.There was no report of serious or systemic side effects.Active trachoma mass treatment with azithromycin 1.5% eye drops is feasible, well tolerated, and effective.

View Article: PubMed Central - PubMed

Affiliation: Faculté des Sciences de la Santé, Niamey, Niger.

ABSTRACT

Background: Following an epidemiological study carried out in 2006 showing a high prevalence of blinding trachoma in the Far North Region of Cameroon, a trachoma elimination programme using the SAFE strategy was initiated: three yearly trachoma mass treatments were to be performed.

Methodology/principal findings: The entire district population (120,000 persons) was treated with azithromycin 1.5% eye drops in February 2008 and January 2009. To assess the effect of treatment on the prevalence of active trachoma, three epidemiological studies were conducted on a representative sample of children aged between 1 and 10 years. The first study was performed just prior to the first treatment, the second just prior to the 2nd treatment and the third one, one year later. The prevalence of active forms of trachoma (TF + TI) dropped from 31.5% (95%CI 26.4-37.5) before treatment to 6.3% (95%CI 4.1-9.6) one year after first treatment; a reduction of nearly 80%. One year after the second treatment, the prevalence decreased to 3.1% (95%CI 2.0-4.9), a total reduction of 90%. Furthermore, there were no more TI cases (only TF). There was no report of serious or systemic side effects. Tolerance was excellent.

Conclusions/significance: Active trachoma mass treatment with azithromycin 1.5% eye drops is feasible, well tolerated, and effective.

Show MeSH

Related in: MedlinePlus

Prevalence of active trachoma in children aged between 1 and 10 years.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2990706&req=5

pntd-0000895-g002: Prevalence of active trachoma in children aged between 1 and 10 years.

Mentions: The prevalence of TF in the study sample was estimated to be 24% (95%CI 20.7–27.5) before treatment, it decreased significantly to 5.8% (95%CI 4.1–8) one year after first annual treatment (p<0.0001) and again significantly (p = 0.0001) to 3.1% one year after the second round of treatment (Table 3), either a decrease of 87%. The prevalence of TI was estimated to be 7.5% (95%CI 5.7–10) before treatment and disappeared after two annual treatments and (0.5% after 1st treatment (p<0.0001) and 0% after second one (p = 0.0005) (Table 3) (Figure 2).


Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops.

Amza A, Goldschmidt P, Einterz E, Huguet P, Olmiere C, Bensaid P, Bella-Assumpta L - PLoS Negl Trop Dis (2010)

Prevalence of active trachoma in children aged between 1 and 10 years.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2990706&req=5

pntd-0000895-g002: Prevalence of active trachoma in children aged between 1 and 10 years.
Mentions: The prevalence of TF in the study sample was estimated to be 24% (95%CI 20.7–27.5) before treatment, it decreased significantly to 5.8% (95%CI 4.1–8) one year after first annual treatment (p<0.0001) and again significantly (p = 0.0001) to 3.1% one year after the second round of treatment (Table 3), either a decrease of 87%. The prevalence of TI was estimated to be 7.5% (95%CI 5.7–10) before treatment and disappeared after two annual treatments and (0.5% after 1st treatment (p<0.0001) and 0% after second one (p = 0.0005) (Table 3) (Figure 2).

Bottom Line: One year after the second treatment, the prevalence decreased to 3.1% (95%CI 2.0-4.9), a total reduction of 90%.There was no report of serious or systemic side effects.Active trachoma mass treatment with azithromycin 1.5% eye drops is feasible, well tolerated, and effective.

View Article: PubMed Central - PubMed

Affiliation: Faculté des Sciences de la Santé, Niamey, Niger.

ABSTRACT

Background: Following an epidemiological study carried out in 2006 showing a high prevalence of blinding trachoma in the Far North Region of Cameroon, a trachoma elimination programme using the SAFE strategy was initiated: three yearly trachoma mass treatments were to be performed.

Methodology/principal findings: The entire district population (120,000 persons) was treated with azithromycin 1.5% eye drops in February 2008 and January 2009. To assess the effect of treatment on the prevalence of active trachoma, three epidemiological studies were conducted on a representative sample of children aged between 1 and 10 years. The first study was performed just prior to the first treatment, the second just prior to the 2nd treatment and the third one, one year later. The prevalence of active forms of trachoma (TF + TI) dropped from 31.5% (95%CI 26.4-37.5) before treatment to 6.3% (95%CI 4.1-9.6) one year after first treatment; a reduction of nearly 80%. One year after the second treatment, the prevalence decreased to 3.1% (95%CI 2.0-4.9), a total reduction of 90%. Furthermore, there were no more TI cases (only TF). There was no report of serious or systemic side effects. Tolerance was excellent.

Conclusions/significance: Active trachoma mass treatment with azithromycin 1.5% eye drops is feasible, well tolerated, and effective.

Show MeSH
Related in: MedlinePlus